Cargando…

Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial

The mRNA-1273 vaccine for coronavirus disease 2019 (COVID-19) demonstrated 93.2% efficacy in reduction of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the blinded portion of the Phase 3 Coronavirus Efficacy (COVE) trial. While mRNA-1273 demonstrated high eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pajon, Rolando, Paila, Yamuna D., Girard, Bethany, Dixon, Groves, Kacena, Katherine, Baden, Lindsey R., El Sahly, Hana M., Essink, Brandon, Mullane, Kathleen M., Frank, Ian, Denhan, Douglas, Kerwin, Edward, Zhao, Xiaoping, Ding, Baoyu, Deng, Weiping, Tomassini, Joanne E., Zhou, Honghong, Leav, Brett, Schödel, Florian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018421/ https://www.ncbi.nlm.nih.gov/pubmed/35145311 http://dx.doi.org/10.1038/s41591-022-01679-5

Ejemplares similares

Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
por: El Sahly, Hana M, et al.
Publicado: (2022)

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
por: Baden, Lindsey R., et al.
Publicado: (2021)

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
por: Ali, Kashif, et al.
Publicado: (2021)

1939. Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves
por: Follmann, Dean, et al.
Publicado: (2023)

mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children
por: Girard, Bethany, et al.
Publicado: (2022)

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
por: Benkeser, David, et al.
Publicado: (2023)

Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial
por: Huang, Ying, et al.
Publicado: (2023)

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
por: El Sahly, Hana M., et al.
Publicado: (2021)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
por: Baden, Lindsey R., et al.
Publicado: (2020)

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
por: Chu, Laurence, et al.
Publicado: (2021)

Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
por: Chalkias, Spyros, et al.
Publicado: (2022)

Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial
por: Lin, Dan-Yu, et al.
Publicado: (2022)

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
por: Chu, Laurence, et al.
Publicado: (2022)

Reply by Cove and Kellum to Swenson
por: Cove, Matthew E., et al.
Publicado: (2020)

Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age
por: Creech, C. Buddy, et al.
Publicado: (2022)

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
por: Chalkias, Spyros, et al.
Publicado: (2022)

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
por: Choi, Angela, et al.
Publicado: (2021)

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
por: Choi, Angela, et al.
Publicado: (2021)

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
por: Anderson, Evan J., et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination
por: Shen, Xiaoying, et al.
Publicado: (2022)

Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
por: Gilbert, Peter B., et al.
Publicado: (2021)

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
por: Gilbert, Peter B., et al.
Publicado: (2021)

Toward Cove-Edged Low Band Gap Graphene Nanoribbons
por: Liu, Junzhi, et al.
Publicado: (2015)

Anatomy of a glacial meltwater discharge event in an Antarctic cove
por: Meredith, Michael P., et al.
Publicado: (2018)

Smooth gap tuning strategy for cove-type graphene nanoribbons
por: de Sousa Araújo Cassiano, Tiago, et al.
Publicado: (2020)

Self-Organized Morphology and Multiscale Structures of CoVE Proteins
por: Sompornpisut, Pornthep, et al.
Publicado: (2021)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial
por: Jochum, Simon, et al.
Publicado: (2021)

Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial
por: Jochum, Simon, et al.
Publicado: (2022)

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273)
por: Leav, Brett, et al.
Publicado: (2022)

Teen COVE study finds Moderna COVID-19 vaccine safe in adolescents
Publicado: (2021)

Coved and Saddleback ST-Segment Elevations: Brugada Phenocopy vs Brugada Syndrome
por: McCullough, Jocelyn, et al.
Publicado: (2022)

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
por: Bruxvoort, Katia J, et al.
Publicado: (2021)

Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19
por: Kirste, Imke, et al.
Publicado: (2022)

Deposit and mobility of cadmium in a marsh-cove ecosystem and the relation to cadmium concentration in biota.
por: Kneip, T J, et al.
Publicado: (1979)

Microbiomes of the Enteropneust, Saccoglossus bromophenolosus, and Associated Marine Intertidal Sediments of Cod Cove, Maine
por: King, Gary M.
Publicado: (2018)

When scientists become detectives: investigating systematic tree poisoning in a protected cove
por: Stoffel, Markus, et al.
Publicado: (2020)

Temperature-Related Short-Term Succession Events of Bacterial Phylotypes in Potter Cove, Antarctica
por: Ilicic, Doris, et al.
Publicado: (2023)

367. Safety and Immunogenicity of a 50-μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in Adolescents
por: Figueroa, Amparo, et al.
Publicado: (2023)

NO SAFETY CONCERNS OBSERVED WHEN THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) AND THE COVID-19 MRNA-1273 BOOSTER WERE CO-ADMINISTERED IN ≥50-YEAR-OLDS
por: Naficy, A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_16l61o964u73tillj2o59cflti